Loading...

PerCP/Cyanine5.5 anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_PerCPCyanine55_CD3e_Antibody_022219
C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
  • 145-2C11_PerCPCyanine55_CD3e_Antibody_022219
    C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3e (clone 145-2C11) PerCP/Cyanine5.5 (left), or Armenian Hamster IgG PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100327 25 µg $82
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100328 100 µg $237
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  2. Fu A, et al. 2022. Cell. 185:1356. PubMed
  3. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  4. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  5. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  6. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  7. Duarte J, et al. 2012. J Immunol. 189:1680. PubMed
  8. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  9. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  10. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  11. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  12. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  13. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  14. Geng Z, et al. 2021. Nat Commun. 12:6584. PubMed
  15. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  16. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  17. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  18. Frisbee AL, et al. 2019. Nat Commun. 10:2712. PubMed
  19. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  20. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  21. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  22. Engler J, et al. 2017. Proc Natl Acad Sci U S A. 114(2):E181-E190. PubMed
  23. Fu B et al. 2017. Immunity. 47(6):1100-1113 . PubMed
  24. Girousse A et al. 2019. Cell Rep. 27(2):323-333 . PubMed
  25. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  26. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  27. Helmersson S, et al. 2013. Am J Pathol. 182:1671. PubMed
  28. Di Luccia B, et al. 2020. Cell Host & Microbe. 27(6):899-908. PubMed
  29. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  30. Liao Y, et al. 2017. Virol J. 10.1186/s12985-017-0801-x. PubMed
  31. Das S, et al. 2019. Oncogene. 383316. PubMed
  32. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  33. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  34. Bertocchi A, et al. 2021. Cancer Cell. 39(5):708-724.e11. PubMed
  35. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  36. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  37. Abu El Maaty MA, et al. 2022. Sci Adv. 8:eabo2295. PubMed
  38. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  39. Katakam A, et al. 2015. Proc Natl Acad Sci U S A. 112: 14664 - 14669. PubMed
  40. Bennion BG, et al. 2020. Cell Reports. 31(11):107771. PubMed
  41. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  42. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  43. Härdle L, et al. 2015. Sci Rep. 5: 15112. PubMed
  44. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  45. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  46. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  47. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  48. Chen Y, et al. 2022. Front Immunol. 13:835690. PubMed
  49. Uddin MJ, et al. 2022. Mucosal Immunol. 15:165. PubMed
  50. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  51. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  52. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  53. Sibilio A, et al. 2022. iScience. 25:103790. PubMed
  54. Li H, et al. 2018. Nat Commun. 9:2830. PubMed
  55. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  56. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  57. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  58. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  59. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  60. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  61. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  62. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  63. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  64. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  65. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  66. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  67. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
  68. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  69. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  70. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  71. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  72. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
  73. Chen B, et al. 2021. Cell. 184:6262. PubMed
  74. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  75. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  76. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  77. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  78. Oh B, et al. 2017. Plast Reconstr Surg Glob Open. 5:e1595. PubMed
  79. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  80. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  81. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  82. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  83. Zhang B, et al. 2021. Front Neurol. 607370:12. PubMed
  84. Young K, et al. 2021. Cell Stem Cell. . PubMed
  85. Gutierrez D, et al. 2014. Diabetes. 63:3827. PubMed
  86. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
RRID
AB_893318 (BioLegend Cat. No. 100327)
AB_893318 (BioLegend Cat. No. 100328)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD3epsilon
Specificity Alt (DOES NOT SHOW ON TDS):
CD3ε
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 4    Revision Date: 02/22/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account